Why Extended-Release Stimulants Are First-Line for ADHD

Turning from diagnosis to treatment, "Why Extended-Release Stimulants Are First-Line for ADHD" explores why extended-release stimulants have replaced older prescribing habits as the adult ADHD standard of care.

With diagnosis established, the panel turns to treatment, and Dr. Feld explains that ADHD is one of the few psychiatric conditions where medication is typically first-line, especially once environmental and behavioral strategies have been tried and symptoms persist. Current guidelines from groups including the American Academy of Family Physicians and the American Academy of Pediatrics recommend extended-release stimulants as first-line treatment starting at age six, sometimes combined with non-stimulants. Dr. Feld notes this is an exciting period in ADHD care, not because of new chemical entities, but because pharmaceutical companies have engineered increasingly sophisticated delivery systems for the same methylphenidate and amphetamine molecules, improving tolerability, adherence, and hours of daily coverage.

The panel recalls that clinicians once started stimulant-naive patients on immediate-release formulations to test responsiveness, a practice Dr. Patel describes as giving "jet fuel to a naive brain" that often led to disastrous first experiences and failed trials. Current guidelines steer providers toward extended-release formulations from the outset specifically to avoid setting patients up for that kind of failure. Because ADHD touches nearly every part of a patient's day, the panel argues medication needs to cover as much of that day as possible, and asking patients to manage multiple doses only adds burden to an already taxed executive function. Extended-release formulations simplify administration to a single daily prescription, reducing pharmacy trips and exposure to shortages. The panel also discusses how differences in individual drug metabolism, from average to slow to fast metabolizers, occasionally make an immediate-release option more appropriate, though extended-release remains the default starting point for nearly all adult patients.

In "Moving Beyond Spot-Treatment to All-Day ADHD Control," the panel challenges a common misconception about when ADHD treatment should actually begin.